The University of Sydney

Project title: Local Regulation of Inflammation for the Treatment of Peripheral Arterial Disease

Peripheral artery disease (PAD) is the most common manifestation of cardiovascular disease in the lower limbs. Advanced PAD severely diminishes quality of life, affecting patients' mobility and, in its most severe form leads to limb amputation and death. In diabetic patients, where advanced PAD often manifests below the knee, the downward spiral of chronic limb-threatening ischemia, tissue loss and amputation, is intractable. Current therapies have major drawbacks that limit their effectiveness.

We have assembled a team of bioengineers, vascular biologists, and clinicians to develop is an injectable treatment for PAD that leaves no permanent device behind. We have developed: a proprietary nanoparticle platform that is easy to functionalise with bioactive agents that increases local drug retention in the vasculature; a new paradigm for the 'switching off' of local inflammation; and a specialised tri-balloon catheter we designed that will target delivery of our nanotherapy to sites of disease.

Working closely with our partners Sydney Local Health Districts and Sydney-based medical technology company Endoluminal Sciences, this grant will facilitate the advancement of our approach towards commercialisation of a therapy that stands to have significant impact on the treatment of PAD.

TTRA Project Round:  One

State:  New South Wales

Project Partners:  

  • Sydney Local Health District
  • Endoluminal Sciences


  • TTRA: $739,128
  • Industry Contribution: $61,113 cash, $696,600 in-kind

Duration:  February 2022 – January 2024

    Website:   |   LinkedIn: University of Sydney

    Twitter:  @docswise   @Sydney_Uni   @SydneyLHD   @SydneyNano